Schroder Investment Management Group decreased its stake in PerkinElmer, Inc. (NYSE:PKI) by 22.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 702,598 shares of the medical research company’s stock after selling 201,069 shares during the quarter. Schroder Investment Management Group owned approximately 0.64% of PerkinElmer worth $51,374,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Bank of New York Mellon Corp grew its position in shares of PerkinElmer by 8.0% during the fourth quarter. Bank of New York Mellon Corp now owns 1,007,210 shares of the medical research company’s stock worth $73,647,000 after purchasing an additional 74,735 shares in the last quarter. Rhumbline Advisers grew its position in shares of PerkinElmer by 2.0% during the fourth quarter. Rhumbline Advisers now owns 173,371 shares of the medical research company’s stock worth $12,677,000 after purchasing an additional 3,329 shares in the last quarter. Vestpro Financial Partners Inc. dba CPF Texas purchased a new stake in shares of PerkinElmer during the fourth quarter worth about $439,000. Capital Fund Management S.A. purchased a new stake in shares of PerkinElmer during the fourth quarter worth about $1,024,000. Finally, State of Wisconsin Investment Board grew its position in shares of PerkinElmer by 6.4% during the fourth quarter. State of Wisconsin Investment Board now owns 25,799 shares of the medical research company’s stock worth $1,886,000 after purchasing an additional 1,544 shares in the last quarter. Institutional investors and hedge funds own 90.06% of the company’s stock.
In related news, Director Alexis P. Michas sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $73.18, for a total transaction of $365,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Frank Anders Wilson sold 37,535 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $70.14, for a total value of $2,632,704.90. The disclosure for this sale can be found here. Insiders have sold a total of 59,812 shares of company stock valued at $4,263,863 over the last three months. 2.20% of the stock is owned by corporate insiders.
Shares of PerkinElmer, Inc. (NYSE PKI) opened at $76.39 on Tuesday. The stock has a market capitalization of $8,420.10, a P/E ratio of 26.16, a PEG ratio of 1.76 and a beta of 0.76. PerkinElmer, Inc. has a one year low of $53.97 and a one year high of $84.49. The company has a quick ratio of 0.90, a current ratio of 1.27 and a debt-to-equity ratio of 0.72.
PerkinElmer (NYSE:PKI) last posted its quarterly earnings data on Thursday, January 25th. The medical research company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.03. The business had revenue of $641.63 million during the quarter, compared to analyst estimates of $619.14 million. PerkinElmer had a return on equity of 13.30% and a net margin of 12.97%. The company’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same period last year, the company earned $0.83 EPS. sell-side analysts predict that PerkinElmer, Inc. will post 3.52 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 10th. Investors of record on Friday, April 13th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.37%. The ex-dividend date is Thursday, April 12th. PerkinElmer’s dividend payout ratio is currently 10.61%.
Several analysts recently issued reports on the company. Robert W. Baird reiterated a “buy” rating and set a $88.00 target price on shares of PerkinElmer in a research report on Friday, January 26th. Barclays increased their price target on PerkinElmer from $69.00 to $73.00 and gave the company an “underweight” rating in a research note on Friday, January 26th. Cowen reissued a “hold” rating and set a $84.00 price target on shares of PerkinElmer in a research note on Friday, January 26th. Zacks Investment Research raised PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a research note on Monday, January 8th. Finally, Evercore ISI initiated coverage on PerkinElmer in a research note on Wednesday, January 3rd. They set an “in-line” rating and a $77.00 price target for the company. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $76.85.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.thelincolnianonline.com/2018/02/20/schroder-investment-management-group-has-51-37-million-holdings-in-perkinelmer-inc-pki.html.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.